Nuformix plc (LON:NFX – Get Free Report) shares were down 12.7% during mid-day trading on Tuesday . The company traded as low as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). Approximately 16,142,512 shares traded hands during trading, a decline of 74% from the average daily volume of 62,608,598 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Up 11.7 %
The firm has a 50 day moving average of GBX 0.05 and a 200 day moving average of GBX 0.10. The firm has a market cap of £548,937.70, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- Canadian Penny Stocks: Can They Make You Rich?
- Oracle Announces Game-Changing News for the AI Industry
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- NYSE Stocks Give Investors a Variety of Quality Options
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
